Compare iShares MSCI Australia ETF (EWA) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Australia ETF vs McKesson Corporation — how do they compare? iShares MSCI Australia ETF trades at $28.62 (market cap $1.17B), while McKesson Corporation trades at $938.84 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 92.7× iShares MSCI Australia ETF's market cap, and McKesson Corporation pays a 0.4% dividend while iShares MSCI Australia ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Australia ETF for 61 Days and McKesson Corporation for 74 Days on average.
| EWA | MCK | |
|---|---|---|
Market Cap | $1.17B | $108.46B |
Volume | 2,121,231 | 712,607 |
Sector | Broad Market / Factor | Health |
52-Week High | $30.43 | $995.69 |
52-Week Low | $24.95 | $725.17 |
Typical Hold Time | 61 Days | 74 Days |
Enterprise Value | — | $115.00B |
Dividend Yield | — | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWA, the iShares MSCI Australia ETF, trades at $28.23 with no recent price movement. Technical indicators show a bearish trend with all moving averages signaling sell, while oscillators remain neutral. The ETF faces headwinds from Australian market pressures, including inflation concerns from rising oil prices. Recent institutional activity shows mixed sentiment with Squarepoint Ops reducing its stake by 91.2% while Cetera Investment Advisers increased holdings by 106.1%.
The outlook for EWA remains cautious amid Australian economic pressures, though some analysts see potential for over 20% upside to $34.83 based on commodity exposure benefits. Key risks include persistent inflation, tight monetary policy, and global commodity volatility. Institutional positioning suggests divided sentiment on near-term prospects.
McKesson (MCK) trades at $930.25, up 2.19% today, with a bullish technical outlook and strong analyst support. The stock shows consistent earnings beats, with Q2 2026 EPS of $9.93 surpassing the $9.56 estimate. Revenue growth is robust, reaching $359.05B in 2025, though net margins are thin at 1.12%. Recent news highlights a key distribution extension with CVS Health through 2032, reinforcing long-term visibility.
The outlook is positive, driven by operational strength and strategic partnerships, but investors face risks from margin pressure and drug pricing uncertainty. With 81% of analysts rating it Buy and a consensus target of $956.43, the stock offers upside, though high RSI levels suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Australia ETF
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
